7,484 Shares in Illumina, Inc. $ILMN Purchased by Capstone Capital Management Ltd

Capstone Capital Management Ltd acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,484 shares of the life sciences company’s stock, valued at approximately $982,000. Illumina makes up about 0.9% of Capstone Capital Management Ltd’s investment portfolio, making the stock its 25th biggest position.

A number of other institutional investors also recently made changes to their positions in the business. Elyxium Wealth LLC purchased a new position in shares of Illumina during the 4th quarter valued at approximately $25,000. Creative Capital Management Investments LLC increased its stake in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares during the last quarter. Board of the Pension Protection Fund acquired a new stake in Illumina in the fourth quarter valued at $26,000. TD Waterhouse Canada Inc. acquired a new stake in Illumina in the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC bought a new position in Illumina during the 4th quarter valued at $26,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Barclays boosted their target price on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Weiss Ratings cut shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Thursday, May 14th. Canaccord Genuity Group cut their price objective on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Finally, Citigroup increased their target price on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $137.75.

Insider Transactions at Illumina

In related news, SVP Christensen Jakob Wedel sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the sale, the senior vice president owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This represents a 12.68% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 332,530 shares of company stock worth $48,303,655. 2.90% of the stock is currently owned by company insiders.

Illumina Trading Down 0.7%

Illumina stock opened at $141.51 on Tuesday. Illumina, Inc. has a 1 year low of $78.55 and a 1 year high of $155.53. The firm’s 50-day moving average is $128.84 and its 200-day moving average is $130.03. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The company has a market cap of $21.41 billion, a P/E ratio of 25.73, a PEG ratio of 2.36 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the business earned $0.97 earnings per share. Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.